Literature DB >> 29968696

Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions.

Piotr Korczyński, Michał Mierzejewski, Rafał Krenke, Aleksandra Safianowska, Richard W Light.   

Abstract

Introduction In contrast to tuberculous pleurisy (TP), no accurate and commonly accepted biochemical marker of malignant pleural effusion (MPE) has been established. Objectives We aimed to evaluate the ability of a previously reported cancer ratio (CR) to discriminate between MPEs and non-MPEs; to test whether age may have additional value in differentiating MPEs from non-MPEs; and if so, to combine lactate dehydrogenase (LDH) and age with other TP biomarkers in search of an index useful in the identification of MPEs. Patients and methods A retrospective analysis of data from 140 patients with malignant (n = 74), tuberculous (n = 37), and parapneumonic (n = 29) pleural effusions was performed. The diagnostic performance of a test to discriminate between MPEs and non-MPEs was evaluated using the receiver operating characteristic curve analysis. Results Three ratios showed the largest area under the curve (AUC): serum LDH to pleural fluid soluble Fas ligand, age to pleural fluid adenosine deaminase (ADA), and serum LDH to pleural fluid interleukin 18; moreover, the ratios were characterized by high sensitivity (95%, 93.2%, and 92.9%, respectively) and fair specificity (64.8%, 71.2%, and 58.5%, respectively) for differentiating MPEs from non-MPEs. The AUC for CR was lower and showed a sensitivity of 94.6% and a specificity of 68.2%. Conclusions Our study showed a lower specificity of the CR for discriminating between MPEs and non-MPEs than previously reported. We demonstrated that the combinations of serum LDH with other pleural fluid biomarkers of TP have a similar diagnostic performance. We also found that age might be an important factor differentiating between MPEs and non-MPEs and proposed a new age to pleural fluid ADA ratio which has a discriminative potential similar to that of the CR.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29968696     DOI: 10.20452/pamw.4278

Source DB:  PubMed          Journal:  Pol Arch Intern Med        ISSN: 0032-3772


  6 in total

1.  Age : pleural fluid ADA ratio and other indicators for differentiating between tubercular and malignant pleural effusions.

Authors:  Jiupeng Zhou; Yuanli Yang; Yongfeng Zhang; Heng Liu; Quanli Dou
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

2.  Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis.

Authors:  Yan-Qiu Han; Lei Zhang; Li Yan; Pei-Heng Ouyang; Peng Li; Zhi-De Hu
Journal:  Ann Transl Med       Date:  2019-10

3.  Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score.

Authors:  Chaichana Chantharakhit; Nantapa Sujaritvanichpong
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

4.  Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion.

Authors:  Zenghua Ren; Ling Xu
Journal:  Clinics (Sao Paulo)       Date:  2021-04-26       Impact factor: 2.365

5.  Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis.

Authors:  Ying Zhang; Xiaoou Li; Junhui Liu; Xueru Hu; Chun Wan; Rui Zhang; Yongchun Shen
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

6.  Value of Cancer Ratio plus and Cancer Ratio Formulation in Distinguishing Malignant Pleural Effusion from Tuberculosis and Parapneumonic Effusion.

Authors:  Mine Gayaf; Ceyda Anar; Mustafa Canbaz; Dursun Tatar; Filiz Güldaval
Journal:  Tanaffos       Date:  2021-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.